Stock Events

Stock Events

Avidity Biosciences 

$72.86
0
+$0.04+0.05% Friday 15:01

Statistics

Day High
73.04
Day Low
72.75
52W High
73.06
52W Low
21.51
Volume
16,770,578
Avg. Volume
2,697,504
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
-1.3
-1.3
-1.3
-1.29
Expected EPS
-1.294117
Actual EPS
N/A

Financials

-3,650.39%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
37.51MRevenue
-1.37BNet Income

Analyst Ratings

$66.22Average Price Target
The highest estimate is 74.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
10%
Hold
90%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNAM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-targeted therapeutics, particularly for rare neuromuscular diseases, directly competing with Avidity's focus on RNA-based therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, making it a direct competitor in the RNA therapy space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapies, targeting the same RNA-based therapeutic approach as Avidity.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, using RNAi technology similar to Avidity's approach.
Moderna
MRNA
Mkt Cap10.61B
Moderna is focused on drug discovery and drug development based on messenger RNA (mRNA), competing in the broader RNA therapeutics field.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE works on individualized cancer medicine and other diseases using mRNA technology, making it a competitor in the RNA-based therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in the development of gene-based medicines, including RNA-targeted therapies, placing it in competition with Avidity.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, indirectly competing in the genetic and RNA therapy space.

About

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.
Show more...
CEO
Ms. Sarah Boyce
Employees
511
Country
US

Listings

BOATS
BOATS
RNA.BOATS
XNAS
US
RNA
XNAS
US
RNAM

0 Comments

Share your thoughts

FAQ

What is Avidity Biosciences stock price today?▼
The current price of RNAM is $72.86 USD — it has increased by +0.05% in the past 24 hours. Watch Avidity Biosciences stock price performance more closely on the chart.
What is Avidity Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Avidity Biosciences stocks are traded under the ticker RNAM.
When is the next Avidity Biosciences earnings date?▼
Avidity Biosciences is going to release the next earnings report on May 12, 2026.
What is Avidity Biosciences revenue for the last year?▼
Avidity Biosciences revenue for the last year amounts to 37.51M USD.
What is Avidity Biosciences net income for the last year?▼
RNAM net income for the last year is -1.37B USD.
How many employees does Avidity Biosciences have?▼
As of April 01, 2026, the company has 511 employees.
When did Avidity Biosciences complete a stock split?▼
Avidity Biosciences has not had any recent stock splits.
Where is Avidity Biosciences headquartered?▼
Avidity Biosciences is headquartered in San Diego, US.